According to the new market research report " HLA Typing for Transplant Market by Technology (SSO-PCR, SSP-PCR, NGS, Sanger’s Sequencing), Products & Services (Instruments, Reagents, Software), Application (Diagnostics, Research), End User (Hospitals, Academia, Diagnostic Center) - Forecast to 2021", published by MarketsandMarkets™,The global HLA typing for transplant market is projected to reach USD 753.9 Million by 2021 from USD 535.0 Million in 2016, at a CAGR of 7.1% from 2016 to 2021.
Don’t miss out on business opportunities in HLA Typing for Transplant Market, visit: https://www.marketsandmarkets.com/requestsampleNew.asp?id=96374742Browse and in-depth TOC on " HLA Typing for Transplant Market "60 - Figures203 - PagesGet Free 10% customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=96374742This report studies the global HLA typing for transplant market over the forecast period of 2016 to 2021.Market growth can be attributed to factors such as the rising number of solid organ, soft tissue, and stem cell transplantations; technological advancements in the field of organ transplantation; increased funding, research grants, and public-private investments; technological shift from serological assays to gene-based HLA profiling; and improving healthcare infrastructure across developing countries.To know about the assumptions considered for the study, download the pdf brochure@https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96374742Growth in the sequencing-based molecular assay segment is mainly driven by the growing market demand for high-throughput DNA sequencers in HLA typing, rising end-user preference for low-cost and efficient DNA sequencing technologies, expansion in application horizons of NGS in tissue typing, and increasing usage of NGS systems among researchers and diagnostic laboratories. The PCR-based molecular assay segment is expected to hold a larger share of the global HLA typing for transplant market for molecular assay technology in 2016.
The report "Drug Screening Market by Product ((Immunoassay Analyzer, Chromatography, Breathalyzer, Rapid Test Device, Assay Kits)), Drug Screening Services, Sample Type (Urine, Hair, Oral), End User (Workplace, Criminal Justice, Hospital) - Global Forecast to 2022", The drug screening market is expected to reach USD 8.63 Billion by 2022 from USD 5.32 Billion in 2017, at a CAGR of 10.2%. This high growth rate is attributed to factors such as growing drug and alcohol consumption; government funding in major markets, enforcement of stringent laws mandating drug and alcohol testing, and regulatory approvals and new product and service launches.Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773The drug screening market was valued at USD 4.86 Billion in 2016 and is expected to reach USD 8.63 Billion by 2022, growing at a CAGR of 10.2% during the forecast period. The base year considered for the study is 2016 and the forecast period is from 2017 to 2022.Global Market Segmentation:The report segments the global market by product and service, sample type, end user, and region.Based on product, the market is segmented into analytical instruments, rapid testing devices, and consumables. Rapid testing devices market is further subsegmented into urine testing devices and oral fluid testing devices. The urine testing devices segment is expected to account for the largest market share in 2017. However, the oral fluid testing devices segment is projected to register highest CAGR during the forecast period. The high growth in this segment is attributed to the benefits it offers such as shorter detection window, non-invasive nature, and low risk of sample tampering.The global market by sample type is segmented into urine, breath, oral fluid, hair, and other samples. The urine sample segment is estimated to account for the largest share in 2017, however, the oral fluid samples segment is expected to register the highest growth rate during the forecast period.Based on end users, the market is segmented into workplaces, criminal justice systems and law enforcement, drug treatment centers, pain management centers, schools and colleges, hospitals, individual users, and drug testing laboratories. In 2017, the workplace testing segment is expected to account for the largest share of the market. The growth of this end-user segment can be attributed to the growing safety concerns in the workplace and the increasing number of organizations that have made regular drug screening mandatory.Get Expert Analysis and Insights of Global Market | Request Sample Report:https://www.marketsandmarkets.com/requestsampleNew.asp?id=162987773What Drives the Market?1. Growing Drug & Alcohol Consumption2. Enforcement of Stringent Laws Mandating Drug and Alcohol Testing3. Presence of Government Funding in Major Markets4. Regulatory Approvals & Product Launches and ServicesGeographical Growth Analysis:The market is dominated by North America, followed by Europe, Asia Pacific, and the Rest of the World (RoW). The dominance of the North American market is attributed to factors such as rising consumption of illicit drugs, availability of government funding to curb drug abuse, and the presence of laws supporting drug screening, and growing burden of accidents due to unsafe levels of alcohol consumption.Key Players and Strategies Adopted by Them:Alere (US), Thermo Fisher (US), Drägerwerk (Germany), OraSure (US), Alfa Scientific Designs (US), Lifeloc (US), MPD, Inc. (US), Premier Biotech (US), Shimadzu (Japan), Siemens Healthineers (US). While, LabCorp (US), Quest Diagnostics (US), Omega Laboratories (US), Psychemedics (US), CRL (US), SureHire (Canada), and CannAmm (Canada) are some of key players offering drug screening services.Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=162987773
In this report, the market is segmented by tool, technology, application, and region. On the basis tool, the synthetic biology market is segmented into oligonucleotides, enzymes, cloning technology kits, chassis organisms, and
xeno-nucleic acids. The chassis organisms segment is expected to grow at the highest rate during the forecast period. The increasing demand for green alternatives (biomass is converted to chemicals using engineered bacteria, yeasts, and other microorganisms) to fossil fuels is a key driver for this segment.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=889
Synthetic biology has an array of applications in the fields of medicine, agriculture, nanotechnology, and industrial biotechnology. This has attracted interests of researchers from across the globe and has led to a rise in funding from public and private organizations, which, in turn, help in the growth of the market.Synthetic Biology Market segmented into :+ The global synthetic biology market is segmented on the basis of tool, technology, application, and region. Based on tools, the market is segmented into oligonucleotides, enzymes, cloning technology kits, chassis organisms, and xeno-nucleic acids.+ By technology, the market is segmented into gene synthesis, genome engineering, cloning and sequencing, next-generation sequencing, site-directed mutagenesis, measurement and modeling, microfluidics, and nanotechnology.+ The market is segmented into medical (pharmaceutical, drug discovery & therapeutics, and artificial tissue and tissue regeneration), industrial (biofuel & renewable energy, industrial enzymes, and biomaterials & green chemicals), food & agriculture, and environmental (bioremediation and biosensing) on the basis of application.Get Sample Copy of This Report@https://www.marketsandmarkets.com/requestsampleNew.asp?id=889What Drives the Market?1. Wide Range of Applications of Synthetic Biology2. Rising R&D Funding and Initiatives in Synthetic Biology3. Increasing Demand for Synthetic Genes and Synthetic Cells4. Increasing Investments in Synthetic Biology CompaniesGeographical Growth Analysis:The market in Europe is expected to register the highest growth rate from 2017 to 2022. The rising international alliances between the European countries and other countries and heavy funding from the government to foster the synthetic biology research in Europe are major factors driving the growth of market in this region. Additionally, factors such as increasing investments for the adoption of novel synthetic biology technologies, rising R&D funding and collaborations are driving the growth of the market in this region.Key Players and Strategies Adopted by Them:Key players in the global Synthetic Biology Market include Thermo Fisher (US), Novozymes (Denmark), Merck KGaA (Germany), Intrexon (US), and Agilent Technologies (US), Amyris (US), GenScript (US), Ginkgo Bioworks (US), Integrated DNA Technologies (US), New England Biolabs (US), Synthetic Genomics (US), and Twist Bioscience (US). These players are increasingly collaborating, and partnering with companies to offer their synthetic oligonucleotides and to develop synthetic organisms.Speak to Analyst @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=889
The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, the launch of new and advanced NIPT products, and increasing maternal age (growth in the risk of chromosomal abnormalities in babies).
Please share your specific interest to serve you better, Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690
What the Market Looks Like?
Predicted to grow at a CAGR of 13.5% during the forecast period,the global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019. The global Non Invasive Prenatal Testing (NIPT)Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.
> By method, the NIPT products market is segmented into ultrasound detection, biochemical screening tests, and cell-free DNA in maternal plasma tests. The cfDNA in maternal plasma tests segment is expected to grow at the highest CAGR during the forecast period.
> Based on application, the non-invasive prenatal testing (NIPT) market is segmented into trisomy, microdeletion syndrome, and other applications (gender identification and the detection of monogenic disorders, Klinefelter syndrome, and Rhesus (Rh) blood type).
> Based on end user, the NIPT products market is classified into diagnostic laboratories and hospitals. In 2019, diagnostic laboratories formed the largest and fastest-growing end users of NIPT products.
Get Sample Copy of This Report
@https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690
What Drives the Market?
The growth of the global market for Non Invasive Prenatal Testing (NIPT) is primarily influenced by the following factors:
• High Risk of Chromosomal Abnormalities With Increasing Maternal Age
• Growing Preference for Noninvasive Techniques Over Invasive Methods
• Improving Reimbursement Scenario for NIPT
• Programs Focusing on Increasing the Awareness of NIPT
Untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period. On the other hand, a dearth of skilled professionals is expected to restrain the growth of this market in the coming years.
Geographical growth scenario of Non Invasive Prenatal Testing (NIPT) :
Geographically, Non Invasive Prenatal Testing (NIPT) market has been studied for North America dominated the market, followed by Europe. The large share of this market can primarily be attributed to the strong economies in the US and Canada, which have allowed for significant investments in technology in this region.
Leading market players and strategies adopted
The NIPT market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)
Read More: https://www.marketsandmarkets.com/PressReleases/non-invasive-prenatal-testing.asp
